• 提示：詳情請下載說明書。

• 產(chǎn)品描述： VE-822 has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.

• 靶點： ATM/ATR

• 體內(nèi)研究：
  80 nM VE-822單獨使用增加MiaPaCa-2和PSN-1細胞停留在G1期的比率。80 nM VE-822消除MiaPaCa-2和PSN-1細胞中富含XRT的G2/M期部分。VE-822單獨作用不大,而80 nM VE-822與XRT和/或gemcitabine聯(lián)用則增強PSN-1細胞中的早期和晚期細胞凋亡。VE-822增加對與pChk1 Ser345阻斷相關(guān)的DNA損傷劑的腫瘤應答。VE-822（80 nM）減弱ATR信號傳導途徑并降低腫瘤細胞對XRT和吉西他濱的應答的存活率。在正常細胞中,80 nM VE-822減弱ATR信號通路強度,但并沒有增強輻射和gemcitabine殺傷正常細胞的能力

• 細胞實驗： VE-822 is dissolved in DMSO and stored, and then diluted with appropriate media before use. Gemcitabine (10 nM) is added 24 h pre-XRT and is replaced with fresh medium before addition of VE-822. PSN-1 cells are treated with VE-822 (80 nM) for 1 h before, through to 18 h after, XRT (6 Gy). Apoptosis is analyzed 48 h after XRT by flow cytometry using an Annexin V-FITC kit with Pl

• 參考文獻：
  1.Fokas E, et al. Cancer Treat Rev, 2013, pii: S0305-7372(13)00065-0. 2.Fokas E, et al. Cell Death Dis, 2012, 3, e441. 3.Konstantinopoulos P A , Cheng S C , Hendrickson A E W , et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial[J]. The Lancet Oncology, 2020, 21(7).

• 溶解性： DMSO:34  mg/mL  (73.3  mM)    Ethanol:<1  mg/mL

• 保存條件： 2-8℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.157 ml	10.786 ml	21.573 ml
  5 mM	0.431 ml	2.157 ml	4.315 ml
  10 mM	0.216 ml	1.079 ml	2.157 ml
  50 mM	0.043 ml	0.216 ml	0.431 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *